# 4D Molecular Therapeutics Inc. (FDMT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $14.97, market value $827 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). 4D Molecular Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 9.0×**. Each dollar of revenue is priced at 9.0×.
- **Price / book: 2.0×**. The shares trade at 2.0× book value; book value is a meaningful part of the valuation.

## Profitability
- **Operating margin: -214.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -164.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -27.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -35.0%**. Return on all capital, debt included, is -35.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -31.6%**. Each dollar of assets produces -31.6% of profit.

## Growth
- **EPS growth (1 yr): 18.8%**. Earnings per share rose 18.8%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.3×**. It would take 0.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 9.39** (quick 9.39). Current assets cover the next year's liabilities 9.39 times.
- **Altman Z-score: 9.38**. A Z-score of 9.38 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. 4D Molecular Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 126.5%** (YTD 99.6%, 3-mo 73.3%). The shares are up 126.5% over twelve months including dividends.
- **From 52-week high: -11.6%** (131.5% above the low). Trading 12% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 1.89** (volatility 81%). Beta of 1.89 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=FDMT · Page: https://foliofundamentals.com/stocks/fdmt

Not investment advice.